Sponsor

GBG Forschungs GmbH

Clinical research sponsor

Published trials56

Recruiting shown7

Roles2

SourceClinicalTrials.gov

Clinical trials

56 shown

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerNCT06201234 · lead sponsor · 2024-12-13

RECRUITING

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerNCT06607757 · lead sponsor · 2024-12-04

RECRUITING

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · lead sponsor · 2023-01-02

RECRUITING

Long-term Safety and Efficacy of GBG Study ParticipantsNCT05739591 · lead sponsor · 2022-10-12

RECRUITING

Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · lead sponsor · 2020-10-28

ACTIVE_NOT_RECRUITING

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerNCT03555877 · lead sponsor · 2018-03-15

COMPLETED

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).NCT03355157 · lead sponsor · 2018-03-01

COMPLETED

Denosumab as an add-on Neoadjuvant Treatment (GeparX)NCT02682693 · lead sponsor · 2017-02-13

COMPLETED

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination DeficiencyNCT02789332 · lead sponsor · 2016-09-01

COMPLETED

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerNCT02685059 · lead sponsor · 2016-06-01

COMPLETED

Dose EScalation Induction of EvERolimusNCT02387099 · lead sponsor · 2015-05-01

COMPLETED

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)NCT02125344 · lead sponsor · 2014-12-01

COMPLETED

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryNCT01864746 · lead sponsor · 2013-10-30

COMPLETED

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and ExemestaneNCT01773460 · lead sponsor · 2013-07-01

TERMINATED

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)NCT01779479 · lead sponsor · 2013-02-01

COMPLETED

Study of Nab-Paclitaxel in High Risk Early Breast CancerNCT01690702 · lead sponsor · 2012-09-01

COMPLETED

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer PatientsNCT01638247 · lead sponsor · 2012-08-01

COMPLETED

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)NCT01583426 · lead sponsor · 2012-07-01

COMPLETED

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing ChemotherapyNCT01594177 · lead sponsor · 2012-05-01

COMPLETED

Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)NCT01534455 · lead sponsor · 2012-02-01

TERMINATED

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast CancerNCT01426880 · lead sponsor · 2011-08-01

COMPLETED

Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)NCT01416558 · lead sponsor · 2011-07-01

TERMINATED

Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast CancerNCT01498458 · lead sponsor · 2010-10-01

COMPLETED

A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast CancerNCT01200212 · lead sponsor · 2009-07-01

TERMINATED

Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the BreastNCT01204437 · lead sponsor · 2009-03-01

COMPLETED

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerNCT00548899 · lead sponsor · 2007-11-01

COMPLETED

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerNCT00567554 · lead sponsor · 2007-10-01

COMPLETED

Efficacy of RAD001 in Breast Cancer Patients With Bone MetastasesNCT00466102 · lead sponsor · 2006-12-01

UNKNOWN

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast CancerNCT00661739 · lead sponsor · 2005-07-01

COMPLETED

Mono Efficacy of Capecitabine (MoniCa)NCT00196820 · lead sponsor · 2005-07-01

COMPLETED

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)NCT00196846 · lead sponsor · 2005-03-01

COMPLETED

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast CancerNCT00288002 · lead sponsor · 2005-01-01

COMPLETED

Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant ChemotherapyNCT00512993 · lead sponsor · 2004-12-01

COMPLETED

A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)NCT00196872 · lead sponsor · 2004-07-01

COMPLETED

Study in Elderly Patients With Early Breast Cancer (ICE)NCT00196859 · lead sponsor · 2004-06-01

COMPLETED

TBP Study With Capecitabine Plus Minus TrastuzumabNCT00148876 · lead sponsor · 2003-09-01

COMPLETED

Breast Cancer in Pregnancy Register StudyNCT00196833 · lead sponsor · 2003-04-01

UNKNOWN

Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast CancerNCT00544765 · lead sponsor · 2002-09-01

COMPLETED

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)NCT00544232 · lead sponsor · 2002-08-01

COMPLETED

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)NCT00795899 · lead sponsor · 2002-01-01

COMPLETED

German Preoperative Adriamycin Docetaxel StudyNCT00543829 · lead sponsor · 1998-04-01

COMPLETED

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast CancerNCT00793377 · lead sponsor

COMPLETED

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · collaborator · 2025-12-18

RECRUITING

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · collaborator · 2022-12-12

RECRUITING

AXillary Surgery After NeoAdjuvant TreatmentNCT04373655 · collaborator · 2020-04-28

RECRUITING

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · collaborator · 2020-12-04

ACTIVE_NOT_RECRUITING

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685 · collaborator · 2017-06-21

ACTIVE_NOT_RECRUITING

Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)NCT03102307 · collaborator · 2017-02-01

COMPLETED

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary SurgeryNCT02466737 · collaborator · 2015-09-01

ACTIVE_NOT_RECRUITING

Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast CancerNCT02481128 · collaborator · 2014-05-01

COMPLETED

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerNCT02032277 · collaborator · 2014-04-02

COMPLETED

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerNCT01816594 · collaborator · 2013-09-03

COMPLETED

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)NCT01772472 · collaborator · 2013-04-03

COMPLETED

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal WomenNCT00545077 · collaborator · 2007-11-06

COMPLETED

Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer PatientsNCT00798070 · collaborator · 2007-02-01

ACTIVE_NOT_RECRUITING

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer PatientsNCT01222052 · collaborator · 2002-01-01

UNKNOWN

Sponsor roles

lead sponsor42

collaborator14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.